Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313366185> ?p ?o ?g. }
Showing items 1 to 78 of
78
with 100 items per page.
- W4313366185 endingPage "135.30" @default.
- W4313366185 startingPage "135.30" @default.
- W4313366185 abstract "Abstract Myeloid Derived Suppressor Cells (MDSCs) are a heterogeneous population of immature myeloid cells that create an immunosuppressive environment by inhibiting T-cell function. MDSCs also promote angiogenesis, tumor invasion, and metastasis. Increased MDSCs in epithelial ovarian cancer (EOC) are been associated with poor prognosis. The aim of our study was to investigate if MDSCs can influence EOC progression and if their depletion would improve immune response and restrict EOC growth. The intraperitoneal ID8 syngeneic mouse EOC model in B6 mice was used. ID8 tumor bearing mice exhibited significantly higher levels of MDSCs (CD11b+Gr1+) in bone marrow, blood, ascites and tumor compared to non-tumor control groups, including both sub-populations; granulocytic (CD11b+Ly6G+Ly6Clo) and monocytic (CD11b+Ly6G−Ly6Chi). Depleting MDSCs either by anti-Gr1 (Ly6G/Ly6C mAb) monoclonal antibody or gemcitabine treatment significantly slowed EOC progression, as reflected by decreased ascites and reduced tumor burden at the peritoneum, bowel, liver, spleen, and kidney. This was accompanied with an increased number of IFNγ-producing CD4 and CD8 T-cells. Adoptive transfer of MDSCs (Gr1hiLy6G+) enhanced ID8 tumor progression, further supporting their pathogenic role in EOC. Moreover, depletion of MDSCs enhanced the effects of anti-PD-1 immunotherapy in the ID8 EOC mouse model. Overall, we report here that depleting MDSCs improves the antitumor immune response, restricts EOC progression, and enhances tumor responsiveness to immunotherapy. Thus, targeting MDSCs is a potential therapeutic modality in EOC that may be beneficial in combination with other immunotherapies." @default.
- W4313366185 created "2023-01-06" @default.
- W4313366185 creator A5003299608 @default.
- W4313366185 creator A5016301747 @default.
- W4313366185 creator A5036827926 @default.
- W4313366185 creator A5048820211 @default.
- W4313366185 creator A5068266659 @default.
- W4313366185 creator A5074885471 @default.
- W4313366185 creator A5085157156 @default.
- W4313366185 date "2019-05-01" @default.
- W4313366185 modified "2023-10-16" @default.
- W4313366185 title "Myeloid derived suppressor cells promote ovarian cancer progression in a murine model of ovarian cancer" @default.
- W4313366185 doi "https://doi.org/10.4049/jimmunol.202.supp.135.30" @default.
- W4313366185 hasPublicationYear "2019" @default.
- W4313366185 type Work @default.
- W4313366185 citedByCount "0" @default.
- W4313366185 crossrefType "journal-article" @default.
- W4313366185 hasAuthorship W4313366185A5003299608 @default.
- W4313366185 hasAuthorship W4313366185A5016301747 @default.
- W4313366185 hasAuthorship W4313366185A5036827926 @default.
- W4313366185 hasAuthorship W4313366185A5048820211 @default.
- W4313366185 hasAuthorship W4313366185A5068266659 @default.
- W4313366185 hasAuthorship W4313366185A5074885471 @default.
- W4313366185 hasAuthorship W4313366185A5085157156 @default.
- W4313366185 hasConcept C121608353 @default.
- W4313366185 hasConcept C126322002 @default.
- W4313366185 hasConcept C167672396 @default.
- W4313366185 hasConcept C179185449 @default.
- W4313366185 hasConcept C203014093 @default.
- W4313366185 hasConcept C2776090121 @default.
- W4313366185 hasConcept C2777701055 @default.
- W4313366185 hasConcept C2779256057 @default.
- W4313366185 hasConcept C2780427987 @default.
- W4313366185 hasConcept C2908647359 @default.
- W4313366185 hasConcept C502942594 @default.
- W4313366185 hasConcept C55721878 @default.
- W4313366185 hasConcept C71924100 @default.
- W4313366185 hasConcept C86803240 @default.
- W4313366185 hasConcept C8891405 @default.
- W4313366185 hasConcept C90375314 @default.
- W4313366185 hasConcept C99454951 @default.
- W4313366185 hasConceptScore W4313366185C121608353 @default.
- W4313366185 hasConceptScore W4313366185C126322002 @default.
- W4313366185 hasConceptScore W4313366185C167672396 @default.
- W4313366185 hasConceptScore W4313366185C179185449 @default.
- W4313366185 hasConceptScore W4313366185C203014093 @default.
- W4313366185 hasConceptScore W4313366185C2776090121 @default.
- W4313366185 hasConceptScore W4313366185C2777701055 @default.
- W4313366185 hasConceptScore W4313366185C2779256057 @default.
- W4313366185 hasConceptScore W4313366185C2780427987 @default.
- W4313366185 hasConceptScore W4313366185C2908647359 @default.
- W4313366185 hasConceptScore W4313366185C502942594 @default.
- W4313366185 hasConceptScore W4313366185C55721878 @default.
- W4313366185 hasConceptScore W4313366185C71924100 @default.
- W4313366185 hasConceptScore W4313366185C86803240 @default.
- W4313366185 hasConceptScore W4313366185C8891405 @default.
- W4313366185 hasConceptScore W4313366185C90375314 @default.
- W4313366185 hasConceptScore W4313366185C99454951 @default.
- W4313366185 hasIssue "1_Supplement" @default.
- W4313366185 hasLocation W43133661851 @default.
- W4313366185 hasOpenAccess W4313366185 @default.
- W4313366185 hasPrimaryLocation W43133661851 @default.
- W4313366185 hasRelatedWork W1996150995 @default.
- W4313366185 hasRelatedWork W2023771859 @default.
- W4313366185 hasRelatedWork W2149329251 @default.
- W4313366185 hasRelatedWork W2380021556 @default.
- W4313366185 hasRelatedWork W2763883091 @default.
- W4313366185 hasRelatedWork W3032549960 @default.
- W4313366185 hasRelatedWork W3180780036 @default.
- W4313366185 hasRelatedWork W4291367166 @default.
- W4313366185 hasRelatedWork W4360983034 @default.
- W4313366185 hasRelatedWork W1564894628 @default.
- W4313366185 hasVolume "202" @default.
- W4313366185 isParatext "false" @default.
- W4313366185 isRetracted "false" @default.
- W4313366185 workType "article" @default.